Enanta Pharmaceuticals, Inc. (ENTA) Fair Value 2026

ENTA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Enanta Pharmaceuticals, Inc. (ENTA) trades at $13.60. QOC: 5.1/10. Value Trap Risk: 26/100 (LOW). 0/13 models active.

Key Facts

Ticker
ENTA
Price
$13.60
Quality Score
5.1/10
Value Trap Risk
26/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ENTA?

0 Intrinsic Value Models vs. Current Price ($13.60)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Enanta Pharmaceuticals, Inc. (ENTA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Enanta Pharmaceuticals, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ENTA?

0 of 13 models are currently active for ENTA. See which stocks rank higher →

How Does ENTA Rank in Biotechnology?

Among 625 Biotechnology stocks, ENTA ranks #278 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Enanta Pharmaceuticals, Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is ENTA a Value Trap?

CirclFi's Value Trap algorithm assigns ENTA a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Enanta Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Enanta Pharmaceuticals, Inc. scores 5.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENTA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Enanta Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

XBITXBiotech Inc.QOC 5.1CLYMClimb Bio, Inc.QOC 5.1ABOSAcumen Pharmaceuticals, Inc.QOC 5.1ORKAOruka Therapeutics, Inc.QOC 5.1CALCCalciMedica, Inc.QOC 5.1ELOXEloxx Pharmaceuticals, Inc.QOC 5.1NRSNNeuroSense Therapeutics Ltd.QOC 4.6EIKNEikon Therapeutics, Inc.QOC 3.3XFORX4 Pharmaceuticals, Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: XBIT · CLYM · ABOS · ORKA · CALC · ELOX · NRSN · EIKN · XFOR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ENTA?

4 companies across all industries closest to ENTA’s Quality of Company score of 5.1/10.

ISOUIsoEnergy Ltd.QOC 5.1FTCIFTC Solar, Inc.QOC 5.1VENUVenu Holding CorporationQOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ISOU · FTCI · VENU · NVDA

Where Does ENTA Sit in CirclFi's Biotechnology Rankings?

ENTA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Enanta Pharmaceuticals, Inc.’s Valuation?

What is Enanta Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Enanta Pharmaceuticals, Inc. (ENTA). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENTA overvalued or undervalued right now?

At $13.60, 0 of 0 active models suggest ENTA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Enanta Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for ENTA?

Enanta Pharmaceuticals, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ENTA?

CirclFi analyzes ENTA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ENTA a value trap in 2026?

Enanta Pharmaceuticals, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Enanta Pharmaceuticals, Inc. (ENTA) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ENTA/ · Methodology
Primary sources for this ENTA valuation
  • Financial statements: Enanta Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001177648) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ENTA as of ; valuations recomputed .